For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Cytek BioSciences Inc (NASDAQ: CTKB) was $5.36 for the day, down -0.56% from the previous closing price of $5.39. In other words, the price has decreased by -$0.56 from its previous closing price. On the day, 0.68 million shares were traded. CTKB stock price reached its highest trading level at $5.5 during the session, while it also had its lowest trading level at $5.33.
Ratios:
Our analysis of CTKB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.48 and its Current Ratio is at 5.17. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.06.
On May 09, 2025, TD Cowen Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $4.
Goldman Downgraded its Buy to Sell on January 31, 2025, whereas the target price for the stock was revised from $7 to $4.50.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 02 ’25 when McCombe William D. bought 35,000 shares for $2.78 per share. The transaction valued at 97,300 led to the insider holds 55,746 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTKB now has a Market Capitalization of 685355520 and an Enterprise Value of 448447488. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.48 while its Price-to-Book (P/B) ratio in mrq is 1.81. Its current Enterprise Value per Revenue stands at 2.278 whereas that against EBITDA is -16.691.
Stock Price History:
The Beta on a monthly basis for CTKB is 1.30, which has changed by -0.17584097 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, CTKB has reached a high of $7.30, while it has fallen to a 52-week low of $2.37. The 50-Day Moving Average of the stock is 21.71%, while the 200-Day Moving Average is calculated to be 37.59%.
Shares Statistics:
CTKB traded an average of 1.14M shares per day over the past three months and 1533180 shares per day over the past ten days. A total of 127.86M shares are outstanding, with a floating share count of 115.90M. Insiders hold about 9.36% of the company’s shares, while institutions hold 62.79% stake in the company. Shares short for CTKB as of 1763078400 were 6639767 with a Short Ratio of 5.82, compared to 1760486400 on 6276347. Therefore, it implies a Short% of Shares Outstanding of 6639767 and a Short% of Float of 6.74.
Earnings Estimates
. The current assessment of Cytek BioSciences Inc (CTKB) involves the perspectives of 2.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.04 and -$0.01 for the fiscal current year, implying an average EPS of $0.01. EPS for the following year is -$0.01, with 2.0 analysts recommending between -$0.01 and -$0.02.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 4 analysts. It ranges from a high estimate of $58.76M to a low estimate of $55.4M. As of. The current estimate, Cytek BioSciences Inc’s year-ago sales were $57.48MFor the next quarter, 4 analysts are estimating revenue of $44.1M. There is a high estimate of $44.9M for the next quarter, whereas the lowest estimate is $42.62M.
A total of 5 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $198.11M, while the lowest revenue estimate was $196M, resulting in an average revenue estimate of $196.71M. In the same quarter a year ago, actual revenue was $200.45MBased on 5 analysts’ estimates, the company’s revenue will be $207.45M in the next fiscal year. The high estimate is $211.82M and the low estimate is $203.3M.
